Amyloidosis: Diagnosis, Treatment, Outcomes
Amyloidosis: Diagnosis, Treatment, Outcomes is a research topic within Molecular Biology. Science Explorer counts 22k research works in it since 1950. 8.6% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the molecular mechanisms, diagnosis, treatment, and prognosis of amyloidosis, with a particular emphasis on transthyretin-related cardiac and familial amyloid polyneuropathy. It covers topics such as RNAi therapy, cardiovascular magnetic resonance, and immunoglobulin light chain involvement.
- Transthyretin
- Cardiac Amyloidosis
- Light Chain Amyloidosis
- RNAi Therapy
- Diagnosis
- Treatment
- Prognosis
- Familial Amyloid Polyneuropathy
- Immunoglobulin Light Chain
- Cardiovascular Magnetic Resonance
- Research works
- 22k fractional, since 1950
- In the world top 10%
- 1.9k per year above
- Top-10% rate
- 8.6% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +39% the tick is no change
Which countries lead Amyloidosis: Diagnosis, Treatment, Outcomes research?
By volume, the United States and China publish the most (1.4k and 385 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.4k works
- 2 China 385 works
- 3 Japan 336 works
- 4 Italy 296 works
- 5 India 197 works
- 6 France 181 works
- 7 United Kingdom 163 works
- 8 Spain 162 works
- 9 Germany 139 works
- 10 Brazil 100 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Amyloidosis: Diagnosis, Treatment, Outcomes research?
By volume in 2022–2025, Cleveland Clinic publishes the most Amyloidosis: Diagnosis, Treatment, Outcomes research, followed by Mayo Clinic and Mayo Clinic in Arizona.
By volume, 2022–2025
- 1 Cleveland ClinicUnited States 40 works
- 2 Mayo ClinicUnited States 36 works
- 3 Mayo Clinic in ArizonaUnited States 33 works
- 4 University College LondonUnited Kingdom 32 works
- 5 Columbia University Irving Medical CenterUnited States 29 works
- 6 Mayo Clinic in FloridaUnited States 22 works
- 7 Medical University of ViennaAustria 22 works
- 8 National and Kapodistrian University of AthensGreece 22 works
- 9 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 21 works
- 10 Kumamoto UniversityJapan 21 works
Who are the leading researchers in Amyloidosis: Diagnosis, Treatment, Outcomes?
The most-cited researchers publishing on Amyloidosis: Diagnosis, Treatment, Outcomes include John C. Morris, Hugo A. Katus and Kaj Blennow.
- 1 John C. Morris United States 5.1k citations
- 2 Hugo A. Katus Germany 3.8k citations
- 3 Kaj Blennow Sweden 3.4k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Amyloidosis: Diagnosis, Treatment, Outcomes research done?
The largest centres of Amyloidosis: Diagnosis, Treatment, Outcomes research in 2022–2025 are New York (United States), Beijing (China), London (United Kingdom) and Boston (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Clarkston, Kumamoto and Rochester.
Largest cities, 2022–2025
Where it is the local speciality
- ClarkstonUS · 20.7 works1082×
- KumamotoJP · 30.5 works32×
- RochesterUS · 36.9 works21×
- ScottsdaleUS · 33.1 works16×
Location quotient: how much more of its research is in Amyloidosis: Diagnosis, Treatment, Outcomes than the world average.
Where is the best place to study Amyloidosis: Diagnosis, Treatment, Outcomes?
Among universities, judged by research, Medical University of Vienna, University College London and Scuola Superiore Sant'Anna score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Medical University of ViennaAustria | 75.7 | 10.6% | 16.8× | 22 | +398.3% |
| 2 | University College LondonUnited Kingdom | 66.5 | 16.5% | 5.5× | 32 | +37.1% |
| 3 | Scuola Superiore Sant'AnnaItaly | 64.0 | 16.4% | 28.9× | 12 | — |
| 4 | Kumamoto UniversityJapan | 61.8 | 12.2% | 36.8× | 21 | +31.9% |
| 5 | National and Kapodistrian University of AthensGreece | 57.1 | 5.9% | 10.1× | 22 | +58.1% |
| 6 | University of PaviaItaly | 55.0 | 16.5% | 8.3× | 10 | +15.6% |
| 7 | Boston UniversityUnited States | 47.6 | 9.3% | 8.0× | 17 | -8.5% |
| 8 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 46.4 | 5.2% | 5.1× | 21 | +235.0% |
| 9 | Harvard UniversityUnited States | 45.0 | 17.7% | 2.3× | 12 | +43.1% |
| 10 | University of PaduaItaly | 43.2 | 18.5% | 3.0× | 10 | +22.3% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Amyloidosis: Diagnosis, Treatment, Outcomes research growing?
Output in 2018–2022 was 39% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Amyloidosis: Diagnosis, Treatment, Outcomes.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.